


**Product Name** : Serdemetan  
**Cat. No.** : PC-42840  
**CAS No.** : 881202-45-5  
**Molecular Formula** : C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>  
**Molecular Weight** : 328.4103  
**Target** : MDM2-p53  
**Solubility** : 10 mM in DMSO



## Biological Activity

Serdemetan (JNJ 26854165) is an anticancer agent that inhibits the function of the E3 ligase **HDM2**, dose-dependently inhibits proliferation in both wild-type and mutant p53 cell lines with IC<sub>50</sub> of 0.25-3  $\mu$ M. Serdemetan (JNJ 26854165) induces p53-mediated apoptosis in acute leukemia cells with wild-type p53, accelerates the proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53, induces S-phase delay and upregulates E2F1 expression in p53 mutant cells. Serdemetan (JNJ 26854165) demonstrates radiosensitizing activity in vitro and in tumor xenografts.

## References

- Kojima K, et al. *Mol Cancer Ther.* 2010 Sep;9(9):2545-57.  
Tabernero J, et al. *Clin Cancer Res.* 2011 Oct 1;17(19):6313-21.  
Chargari C, et al. *Cancer Lett.* 2011 Dec 22;312(2):209-18.  
Jones RJ, et al. *J Pharmacol Exp Ther.* 2013 Sep;346(3):381-92.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com